Regulatory Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar Big Molecule WatchOn March 30, 2026, Teva Pharmaceutical Industries Ltd.RegulatoryRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Big Molecule Watch On March 30, 2026, Teva Pharmaceutical Industries Ltd. RegulatoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly launches GLP-1 pill, kicking off showdown with Novo NordiskNext: Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
